U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Cranial hyperostosis

MedGen UID:
318629
Concept ID:
C1832451
Finding
Synonym: Hyperostosis of cranial vault
 
HPO: HP:0004437

Definition

Excessive growth of the bones of cranium, i.e., of the skull. [from HPO]

Conditions with this feature

Hurler syndrome
MedGen UID:
39698
Concept ID:
C0086795
Disease or Syndrome
Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.
Osteopetrosis with renal tubular acidosis
MedGen UID:
91042
Concept ID:
C0345407
Disease or Syndrome
Osteopetrosis is a bone disease that makes bone tissue abnormally compact and dense and also prone to breakage (fracture). Researchers have described several major types of osteopetrosis, which are usually distinguished by their pattern of inheritance: autosomal dominant or autosomal recessive. The different types of the disorder can also be distinguished by the severity of their signs and symptoms.\n\nAutosomal dominant osteopetrosis (ADO), which is also called Albers-Schönberg disease, is typically the mildest type of the disorder. Some affected individuals have no symptoms. In affected people with no symptoms, the unusually dense bones may be discovered by accident when an x-ray is done for another reason. \n\nIn individuals with ADO who develop signs and symptoms, the major features of the condition include multiple bone fractures after minor injury, abnormal side-to-side curvature of the spine (scoliosis) or other spinal abnormalities, arthritis in the hips, and a bone infection called osteomyelitis. These problems usually become apparent in late childhood or adolescence.\n\nAutosomal recessive osteopetrosis (ARO) is a more severe form of the disorder that becomes apparent in early infancy. Affected individuals have a high risk of bone fracture resulting from seemingly minor bumps and falls. Their abnormally dense skull bones pinch nerves in the head and face (cranial nerves), often resulting in vision loss, hearing loss, and paralysis of facial muscles. Dense bones can also impair the function of bone marrow, preventing it from producing new blood cells and immune system cells. As a result, people with severe osteopetrosis are at risk of abnormal bleeding, a shortage of red blood cells (anemia), and recurrent infections. In the most severe cases, these bone marrow abnormalities can be life-threatening in infancy or early childhood.\n\nA few individuals have been diagnosed with intermediate autosomal osteopetrosis (IAO), a form of the disorder that can have either an autosomal dominant or an autosomal recessive pattern of inheritance. The signs and symptoms of this condition become noticeable in childhood and include an increased risk of bone fracture and anemia. People with this form of the disorder typically do not have life-threatening bone marrow abnormalities. However, some affected individuals have had abnormal calcium deposits (calcifications) in the brain, intellectual disability, and a form of kidney disease called renal tubular acidosis.\n\nOther features of autosomal recessive osteopetrosis can include slow growth and short stature, dental abnormalities, and an enlarged liver and spleen (hepatosplenomegaly). Depending on the genetic changes involved, people with severe osteopetrosis can also have brain abnormalities, intellectual disability, or recurrent seizures (epilepsy).
Hyperphosphatasemia tarda
MedGen UID:
98484
Concept ID:
C0432272
Disease or Syndrome
SOST-related sclerosing bone dysplasias include sclerosteosis and van Buchem disease, both disorders of progressive bone overgrowth due to increased bone formation. The major clinical features of sclerosteosis are progressive skeletal overgrowth, most pronounced in the skull and mandible, and variable syndactyly, usually of the second (index) and third (middle) fingers. Affected individuals appear normal at birth except for syndactyly. Facial distortion due to bossing of the forehead and mandibular overgrowth is seen in nearly all individuals and becomes apparent in early childhood with progression into adulthood. Hyperostosis of the skull results in narrowing of the foramina, causing entrapment of the seventh cranial nerve (leading to facial palsy) with other, less common nerve entrapment syndromes including visual loss (2nd cranial nerve), neuralgia or anosmia (5th cranial nerve), and sensory hearing loss (8th cranial nerve). In sclerosteosis, hyperostosis of the calvarium reduces intracranial volume, increasing the risk for potentially lethal elevation of intracranial pressure. Survival of individuals with sclerosteosis into old age is unusual, but not unprecedented. The manifestations of van Buchem disease are generally milder than sclerosteosis and syndactyly is absent; life span appears to be normal.
Ectodermal dysplasia with natal teeth, Turnpenny type
MedGen UID:
371331
Concept ID:
C1832444
Disease or Syndrome
A rare disorder with manifestation of hypo or oligodontia and acanthosis nigricans. It has been described in four generations of one family. Onset generally occurs during adolescence. Some patients are born with multiple teeth. Hair anomalies (sparse body and scalp hair) also reported. Inheritance is autosomal dominant.
Autosomal recessive osteopetrosis 2
MedGen UID:
342420
Concept ID:
C1850126
Disease or Syndrome
Osteopetrosis is a bone disease that makes bone tissue abnormally compact and dense and also prone to breakage (fracture). Researchers have described several major types of osteopetrosis, which are usually distinguished by their pattern of inheritance: autosomal dominant or autosomal recessive. The different types of the disorder can also be distinguished by the severity of their signs and symptoms.\n\nAutosomal dominant osteopetrosis (ADO), which is also called Albers-Schönberg disease, is typically the mildest type of the disorder. Some affected individuals have no symptoms. In affected people with no symptoms, the unusually dense bones may be discovered by accident when an x-ray is done for another reason. \n\nIn individuals with ADO who develop signs and symptoms, the major features of the condition include multiple bone fractures after minor injury, abnormal side-to-side curvature of the spine (scoliosis) or other spinal abnormalities, arthritis in the hips, and a bone infection called osteomyelitis. These problems usually become apparent in late childhood or adolescence.\n\nAutosomal recessive osteopetrosis (ARO) is a more severe form of the disorder that becomes apparent in early infancy. Affected individuals have a high risk of bone fracture resulting from seemingly minor bumps and falls. Their abnormally dense skull bones pinch nerves in the head and face (cranial nerves), often resulting in vision loss, hearing loss, and paralysis of facial muscles. Dense bones can also impair the function of bone marrow, preventing it from producing new blood cells and immune system cells. As a result, people with severe osteopetrosis are at risk of abnormal bleeding, a shortage of red blood cells (anemia), and recurrent infections. In the most severe cases, these bone marrow abnormalities can be life-threatening in infancy or early childhood.\n\nA few individuals have been diagnosed with intermediate autosomal osteopetrosis (IAO), a form of the disorder that can have either an autosomal dominant or an autosomal recessive pattern of inheritance. The signs and symptoms of this condition become noticeable in childhood and include an increased risk of bone fracture and anemia. People with this form of the disorder typically do not have life-threatening bone marrow abnormalities. However, some affected individuals have had abnormal calcium deposits (calcifications) in the brain, intellectual disability, and a form of kidney disease called renal tubular acidosis.\n\nOther features of autosomal recessive osteopetrosis can include slow growth and short stature, dental abnormalities, and an enlarged liver and spleen (hepatosplenomegaly). Depending on the genetic changes involved, people with severe osteopetrosis can also have brain abnormalities, intellectual disability, or recurrent seizures (epilepsy).
Craniometaphyseal dysplasia, autosomal dominant
MedGen UID:
338945
Concept ID:
C1852502
Disease or Syndrome
Autosomal dominant craniometaphyseal dysplasia (designated AD-CMD in this review) is characterized by progressive diffuse hyperostosis of cranial bones evident clinically as wide nasal bridge, paranasal bossing, widely spaced eyes with an increase in bizygomatic width, and prominent mandible. Development of dentition may be delayed and teeth may fail to erupt as a result of hyperostosis and sclerosis of alveolar bone. Progressive thickening of craniofacial bones continues throughout life, often resulting in narrowing of the cranial foramina, including the foramen magnum. If untreated, compression of cranial nerves can lead to disabling conditions such as facial palsy, blindness, or deafness (conductive and/or sensorineural hearing loss). In individuals with typical uncomplicated AD-CMD life expectancy is normal; in those with severe AD-CMD life expectancy can be reduced as a result of compression of the foramen magnum.
Autosomal recessive osteopetrosis 5
MedGen UID:
409627
Concept ID:
C1968603
Disease or Syndrome
Autosomal recessive osteopetrosis-5 (OPTB5) is a form of infantile malignant osteopetrosis, characterized by defective osteoclast function resulting in decreased bone resorption and generalized osteosclerosis. Defective resorption causes development of densely sclerotic fragile bones and progressive obliteration of the marrow spaces and cranial foramina. Marrow obliteration is associated with extramedullary hematopoiesis and hepatosplenomegaly, and results in anemia and thrombocytopenia, whereas nerve entrapment accounts for progressive blindness and hearing loss. Other major manifestations include failure to thrive, pathologic fractures, and increased infection rate. Most affected children succumb to severe bone marrow failure and overwhelming infection in the first few years of life (summary by Quarello et al., 2004).
CLOVES syndrome
MedGen UID:
442876
Concept ID:
C2752042
Disease or Syndrome
PIK3CA-related overgrowth spectrum (PROS) encompasses a range of clinical findings in which the core features are congenital or early-childhood onset of segmental/focal overgrowth with or without cellular dysplasia. Prior to the identification of PIK3CA as the causative gene, PROS was separated into distinct clinical syndromes based on the tissues and/or organs involved (e.g., MCAP [megalencephaly-capillary malformation] syndrome and CLOVES [congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies] syndrome). The predominant areas of overgrowth include the brain, limbs (including fingers and toes), trunk (including abdomen and chest), and face, all usually in an asymmetric distribution. Generalized brain overgrowth may be accompanied by secondary overgrowth of specific brain structures resulting in ventriculomegaly, a markedly thick corpus callosum, and cerebellar tonsillar ectopia with crowding of the posterior fossa. Vascular malformations may include capillary, venous, and less frequently, arterial or mixed (capillary-lymphatic-venous or arteriovenous) malformations. Lymphatic malformations may be in various locations (internal and/or external) and can cause various clinical issues, including swelling, pain, and occasionally localized bleeding secondary to trauma. Lipomatous overgrowth may occur ipsilateral or contralateral to a vascular malformation, if present. The degree of intellectual disability appears to be mostly related to the presence and severity of seizures, cortical dysplasia (e.g., polymicrogyria), and hydrocephalus. Many children have feeding difficulties that are often multifactorial in nature. Endocrine issues affect a small number of individuals and most commonly include hypoglycemia (largely hypoinsulinemic hypoketotic hypoglycemia), hypothyroidism, and growth hormone deficiency.

Professional guidelines

PubMed

Shafarenko MS, Klieb HB, Antonyshyn OM
J Craniofac Surg 2023 May 1;34(3):e330-e331. Epub 2023 Mar 13 doi: 10.1097/SCS.0000000000009259. PMID: 36907844
Rosato S, Unger S, Campos-Xavier B, Caraffi SG, Beltrami L, Pollazzon M, Ivanovski I, Castori M, Bonasoni MP, Comitini G, Nikkels PGJ, Lindstrom K, Umandap C, Superti-Furga A, Garavelli L
Genes (Basel) 2022 Jan 28;13(2) doi: 10.3390/genes13020261. PMID: 35205306Free PMC Article
Tolstunov L
Compend Contin Educ Dent 2011 Apr;32(3):62-6. PMID: 21560744

Recent clinical studies

Etiology

Godfrey D, Stone RT, Lee M, Chitnis T, Santoro JD
Nutr Neurosci 2022 Aug;25(8):1697-1703. Epub 2021 Mar 5 doi: 10.1080/1028415X.2021.1892252. PMID: 33666531
Wong T, Herschman Y, Patel NV, Patel T, Hanft S
World Neurosurg 2017 Jun;102:555-560. Epub 2017 Jan 27 doi: 10.1016/j.wneu.2017.01.061. PMID: 28137547
Gannagé-Yared MH, Makrythanasis P, Chouery E, Sobacchi C, Mehawej C, Santoni FA, Guipponi M, Antonarakis SE, Hamamy H, Mégarbané A
Bone 2014 Nov;68:142-5. Epub 2014 Aug 30 doi: 10.1016/j.bone.2014.08.014. PMID: 25180662
Sakamoto Y, Nakajima H, Kishi K, Shimizu R, Nakajima T
J Craniofac Surg 2010 Mar;21(2):414-8. doi: 10.1097/SCS.0b013e3181cfa7f0. PMID: 20216456
Nogueira RL, Teixeira RC, Lima MC, Sant'ana E, Santos CF
Dentomaxillofac Radiol 2007 Sep;36(6):367-71. doi: 10.1259/dmfr/42508276. PMID: 17699709

Diagnosis

Yapijakis C, Vylliotis A, Angelopoulou A, Adamopoulou M, Chrousos GP, Voumvourakis C
Adv Exp Med Biol 2021;1339:319-323. doi: 10.1007/978-3-030-78787-5_38. PMID: 35023120
Keppler-Noreuil KM, Baker EH, Sapp JC, Lindhurst MJ, Biesecker LG
Am J Med Genet A 2016 Oct;170(10):2605-10. Epub 2016 Aug 23 doi: 10.1002/ajmg.a.37737. PMID: 27550858Free PMC Article
Gannagé-Yared MH, Makrythanasis P, Chouery E, Sobacchi C, Mehawej C, Santoni FA, Guipponi M, Antonarakis SE, Hamamy H, Mégarbané A
Bone 2014 Nov;68:142-5. Epub 2014 Aug 30 doi: 10.1016/j.bone.2014.08.014. PMID: 25180662
Mocco J, Komotar RJ, Zacharia BE, Feldstein NA, Bruce JN
Neurosurgery 2005 Jul;57(1 Suppl):E212; discussion E212. doi: 10.1227/01.neu.0000163686.75095.b8. PMID: 15987595
Spiro PC, Hamersma H, Beighton P
S Afr Med J 1975 May 17;49(21):839-42. PMID: 1135718

Therapy

Godfrey D, Stone RT, Lee M, Chitnis T, Santoro JD
Nutr Neurosci 2022 Aug;25(8):1697-1703. Epub 2021 Mar 5 doi: 10.1080/1028415X.2021.1892252. PMID: 33666531
Songdej N
J Pediatr Hematol Oncol 2014 Mar;36(2):148-9. doi: 10.1097/MPH.0b013e3182830d56. PMID: 23459379

Prognosis

Manara R, Priante E, Grimaldi M, Santoro L, Astarita L, Barone R, Concolino D, Di Rocco M, Donati MA, Fecarotta S, Ficcadenti A, Fiumara A, Furlan F, Giovannini I, Lilliu F, Mardari R, Polonara G, Procopio E, Rampazzo A, Rossi A, Sanna G, Parini R, Scarpa M
J Inherit Metab Dis 2011 Jun;34(3):763-80. Epub 2011 Apr 5 doi: 10.1007/s10545-011-9317-5. PMID: 21465231
Sakamoto Y, Nakajima H, Kishi K, Shimizu R, Nakajima T
J Craniofac Surg 2010 Mar;21(2):414-8. doi: 10.1097/SCS.0b013e3181cfa7f0. PMID: 20216456
Nogueira RL, Teixeira RC, Lima MC, Sant'ana E, Santos CF
Dentomaxillofac Radiol 2007 Sep;36(6):367-71. doi: 10.1259/dmfr/42508276. PMID: 17699709
Spiro PC, Hamersma H, Beighton P
S Afr Med J 1975 May 17;49(21):839-42. PMID: 1135718

Clinical prediction guides

Sakamoto Y, Nakajima H, Kishi K, Shimizu R, Nakajima T
J Craniofac Surg 2010 Mar;21(2):414-8. doi: 10.1097/SCS.0b013e3181cfa7f0. PMID: 20216456
Villari N, Fornaciari G, Lippi D, Cerinic MM, Ginestroni A, Pellicanò G, Mascalchi M
Radiographics 2009 Nov;29(7):2101-14. doi: 10.1148/rg.297085212. PMID: 19926765
Janssens K, Gershoni-Baruch R, Van Hul E, Brik R, Guañabens N, Migone N, Verbruggen LA, Ralston SH, Bonduelle M, Van Maldergem L, Vanhoenacker F, Van Hul W
J Med Genet 2000 Apr;37(4):245-9. doi: 10.1136/jmg.37.4.245. PMID: 10745041Free PMC Article
Ghadami M, Makita Y, Yoshida K, Nishimura G, Fukushima Y, Wakui K, Ikegawa S, Yamada K, Kondo S, Niikawa N, Tomita Ha
Am J Hum Genet 2000 Jan;66(1):143-7. doi: 10.1086/302728. PMID: 10631145Free PMC Article
Avrahami E, Katz A, Bornstein N, Korczyn AD
J Neurol Neurosurg Psychiatry 1987 Apr;50(4):435-8. doi: 10.1136/jnnp.50.4.435. PMID: 3585355Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...